Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 457 to 463 of 463 entries
Sorted by: Best Match Show Resources per page
Comment on "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark".

Journal of the American Academy of Dermatology

van Veelen A, Nielen JTH, van Geel R, Croes S.
PMID: 30771418
J Am Acad Dermatol. 2021 Dec;85(6):e357. doi: 10.1016/j.jaad.2019.01.087. Epub 2019 Feb 13.

No abstract available.

Cite
van Veelen A, Nielen JTH, van Geel R, et al. Comment on "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark". J Am Acad Dermatol. 2019;85(6):e357doi: 10.1016/j.jaad.2019.01.087.
van Veelen, A., Nielen, J. T. H., van Geel, R., & Croes, S. (2021). Comment on "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark". Journal of the American Academy of Dermatology, 85(6), e357. https://doi.org/10.1016/j.jaad.2019.01.087
van Veelen, Ard, et al. "Comment on "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark"." Journal of the American Academy of Dermatology vol. 85,6 (2021): e357. doi: https://doi.org/10.1016/j.jaad.2019.01.087
van Veelen A, Nielen JTH, van Geel R, Croes S. Comment on "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark". J Am Acad Dermatol. 2021 Dec;85(6):e357. doi: 10.1016/j.jaad.2019.01.087. Epub 2019 Feb 13. PMID: 30771418.
Copy Download .nbib Format: NLM
Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination.

Blood pressure monitoring

Zhang D, Huang QF, Li Y, Wang JG.
PMID: 34128490
Blood Press Monit. 2021 Dec 01;26(6):413-418. doi: 10.1097/MBP.0000000000000554.

OBJECTIVE: We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination.METHODS: The study participants were 449 patients who completed the study. Analysis...

Cite
Zhang D, Huang QF, Li Y, et al. Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. Blood Press Monit. 2021;26(6):413-418doi: 10.1097/MBP.0000000000000554.
Zhang, D., Huang, Q. F., Li, Y., & Wang, J. G. (2021). Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. Blood pressure monitoring, 26(6), 413-418. https://doi.org/10.1097/MBP.0000000000000554
Zhang, Di, et al. "Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination." Blood pressure monitoring vol. 26,6 (2021): 413-418. doi: https://doi.org/10.1097/MBP.0000000000000554
Zhang D, Huang QF, Li Y, Wang JG. Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. Blood Press Monit. 2021 Dec 01;26(6):413-418. doi: 10.1097/MBP.0000000000000554. PMID: 34128490.
Copy Download .nbib Format: NLM
Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review.

International journal of cardiology. Cardiovascular risk and prevention

Ajayi AAL, Ajayi OE.
PMID: 34825245
Int J Cardiol Cardiovasc Risk Prev. 2021 Oct 28;11:200111. doi: 10.1016/j.ijcrp.2021.200111. eCollection 2021 Dec.

BACKGROUND: Hypertension (HT) prevalence, Uncontrolled Blood Pressure (UBP), morbidity and mortality are highest in Sub-Saharan Africa (SSA). Correlating pathophysiology of HT to pharmaco-therapy with antihypertensive drugs (AHD) may bring amelioration. METHODS AND RESULTS: 14 published therapeutic audits in 4...

Cite
Ajayi AAL, Ajayi OE. Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review. Int J Cardiol Cardiovasc Risk Prev. 2021;11:200111doi: 10.1016/j.ijcrp.2021.200111.
Ajayi, A. A. L., & Ajayi, O. E. (2021). Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review. International journal of cardiology. Cardiovascular risk and prevention, 11200111. https://doi.org/10.1016/j.ijcrp.2021.200111
Ajayi, A A L, and Ajayi, O E. "Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review." International journal of cardiology. Cardiovascular risk and prevention vol. 11 (2021): 200111. doi: https://doi.org/10.1016/j.ijcrp.2021.200111
Ajayi AAL, Ajayi OE. Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review. Int J Cardiol Cardiovasc Risk Prev. 2021 Oct 28;11:200111. doi: 10.1016/j.ijcrp.2021.200111. eCollection 2021 Dec. PMID: 34825245; PMCID: PMC8605193.
Copy Download .nbib Format: NLM
Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population.

International journal of dermatology

Tiba APL, Cury-Martins J, Miyashiro DR, Sanches JA.
PMID: 34480765
Int J Dermatol. 2021 Sep 04; doi: 10.1111/ijd.15900. Epub 2021 Sep 04.

No abstract available.

Cite
Tiba APL, Cury-Martins J, Miyashiro DR, et al. Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population. Int J Dermatol. 2021;doi: 10.1111/ijd.15900.
Tiba, A. P. L., Cury-Martins, J., Miyashiro, D. R., & Sanches, J. A. (2021). Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population. International journal of dermatology, . https://doi.org/10.1111/ijd.15900
Tiba, Ana P L, et al. "Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population." International journal of dermatology vol. (2021). doi: https://doi.org/10.1111/ijd.15900
Tiba APL, Cury-Martins J, Miyashiro DR, Sanches JA. Use of hydrochlorothiazide and risk of nonmelanoma skin cancer: a pilot study in the Brazilian population. Int J Dermatol. 2021 Sep 04; doi: 10.1111/ijd.15900. Epub 2021 Sep 04. PMID: 34480765.
Copy Download .nbib Format: NLM
Ion Transport Modulators as Antimycobacterial Agents.

Tuberculosis research and treatment

Mitini-Nkhoma SC, Fernando N, Ishaka GKD, Handunnetti SM, Pathirana SL.
PMID: 33294223
Tuberc Res Treat. 2020 Nov 20;2020:3767915. doi: 10.1155/2020/3767915. eCollection 2020.

There is an urgent need for better and safer therapeutic interventions for tuberculosis (TB). We assessed the effects of FDA-approved ion transport modulators, namely, ambroxol HCl, amiloride HCl, diazoxide, digoxin, furosemide, hydrochlorothiazide (HCTZ), metformin, omeprazole, pantoprazole, phenytoin, verapamil, and...

Cite
Mitini-Nkhoma SC, Fernando N, Ishaka GKD, et al. Ion Transport Modulators as Antimycobacterial Agents. Tuberc Res Treat. 2020;2020:3767915doi: 10.1155/2020/3767915.
Mitini-Nkhoma, S. C., Fernando, N., Ishaka, G. K. D., Handunnetti, S. M., & Pathirana, S. L. (2020). Ion Transport Modulators as Antimycobacterial Agents. Tuberculosis research and treatment, 20203767915. https://doi.org/10.1155/2020/3767915
Mitini-Nkhoma, Steven C, et al. "Ion Transport Modulators as Antimycobacterial Agents." Tuberculosis research and treatment vol. 2020 (2020): 3767915. doi: https://doi.org/10.1155/2020/3767915
Mitini-Nkhoma SC, Fernando N, Ishaka GKD, Handunnetti SM, Pathirana SL. Ion Transport Modulators as Antimycobacterial Agents. Tuberc Res Treat. 2020 Nov 20;2020:3767915. doi: 10.1155/2020/3767915. eCollection 2020. PMID: 33294223; PMCID: PMC7700046.
Copy Download .nbib Format: NLM
Transformation of organic micropollutants along hyporheic flow in bedforms of river-simulating flumes.

Scientific reports

Jaeger A, Posselt M, Schaper JL, Betterle A, Rutere C, Coll C, Mechelke J, Raza M, Meinikmann K, Portmann A, Blaen PJ, Horn MA, Krause S, Lewandowski J.
PMID: 34158517
Sci Rep. 2021 Jun 22;11(1):13034. doi: 10.1038/s41598-021-91519-2.

Urban streams receive increasing loads of organic micropollutants from treated wastewaters. A comprehensive understanding of the in-stream fate of micropollutants is thus of high interest for water quality management. Bedforms induce pumping effects considerably contributing to whole stream hyporheic...

Cite
Jaeger A, Posselt M, Schaper JL, et al. Transformation of organic micropollutants along hyporheic flow in bedforms of river-simulating flumes. Sci Rep. 2021;11(1):13034doi: 10.1038/s41598-021-91519-2.
Jaeger, A., Posselt, M., Schaper, J. L., Betterle, A., Rutere, C., Coll, C., Mechelke, J., Raza, M., Meinikmann, K., Portmann, A., Blaen, P. J., Horn, M. A., Krause, S., & Lewandowski, J. (2021). Transformation of organic micropollutants along hyporheic flow in bedforms of river-simulating flumes. Scientific reports, 11(1), 13034. https://doi.org/10.1038/s41598-021-91519-2
Jaeger, Anna, et al. "Transformation of organic micropollutants along hyporheic flow in bedforms of river-simulating flumes." Scientific reports vol. 11,1 (2021): 13034. doi: https://doi.org/10.1038/s41598-021-91519-2
Jaeger A, Posselt M, Schaper JL, Betterle A, Rutere C, Coll C, Mechelke J, Raza M, Meinikmann K, Portmann A, Blaen PJ, Horn MA, Krause S, Lewandowski J. Transformation of organic micropollutants along hyporheic flow in bedforms of river-simulating flumes. Sci Rep. 2021 Jun 22;11(1):13034. doi: 10.1038/s41598-021-91519-2. PMID: 34158517; PMCID: PMC8219703.
Copy Download .nbib Format: NLM
Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.

Hypertension (Dallas, Tex. : 1979)

Meariman JK, Sutphen JC, Gao J, Kapusta DR.
PMID: 34852633
Hypertension. 2022 Feb;79(2):379-390. doi: 10.1161/HYPERTENSIONAHA.121.18503. Epub 2021 Dec 02.

Nalfurafine is a G-protein-biased KOR (kappa opioid receptor) agonist that produces analgesia and lacks central nervous system adverse effects. Here, we examined the cardiovascular and renal responses to intravenous and oral nalfurafine alone and in combination with furosemide, hydrochlorothiazide,...

Cite
Meariman JK, Sutphen JC, Gao J, et al. Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics. Hypertension. 2021;79(2):379-390doi: 10.1161/HYPERTENSIONAHA.121.18503.
Meariman, J. K., Sutphen, J. C., Gao, J., & Kapusta, D. R. (2022). Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics. Hypertension (Dallas, Tex. : 1979), 79(2), 379-390. https://doi.org/10.1161/HYPERTENSIONAHA.121.18503
Meariman, Jacob K, et al. "Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics." Hypertension (Dallas, Tex. : 1979) vol. 79,2 (2022): 379-390. doi: https://doi.org/10.1161/HYPERTENSIONAHA.121.18503
Meariman JK, Sutphen JC, Gao J, Kapusta DR. Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics. Hypertension. 2022 Feb;79(2):379-390. doi: 10.1161/HYPERTENSIONAHA.121.18503. Epub 2021 Dec 02. PMID: 34852633; PMCID: PMC8755620.
Copy Download .nbib Format: NLM
Showing 457 to 463 of 463 entries